Immunotherapy combo shows promise in cervical cancer trial
NCT ID NCT03298893
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested whether adding the immunotherapy drug nivolumab to standard chemoradiation is safe for people with locally advanced cervical cancer. Twenty-one adults received nivolumab alongside cisplatin and radiation, followed by up to six months of nivolumab alone. The main goal was to check for serious side effects, with a secondary look at how well the cancer responded.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (a cancer immunotherapy drug) combined with cisplatin chemotherapy and radiation therapy
What this could lead to
If successful, this combination could improve outcomes for locally advanced cervical cancer by adding immunotherapy to standard chemoradiation.
What could go wrong
This is a small, early-phase study (21 participants) focused on safety, not proof of effectiveness. Adding immunotherapy may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Européen Georges Pompidou
Paris, 75015, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie Hopital René Huguenin
Saint-Cloud, 9220, France